Raul Rodriguez, CEO of Rigel Pharmaceuticals
Rigel churns out another late-stage clinical failure — this time in Covid-19
In the waning days of the Covid-19 pandemic, one penny stock biotech is reporting a close miss for its sole approved drug. But alas, a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
